Dermata Therapeutics, Inc. (NASDAQ:DRMA – Get Free Report) shares traded up 10% on Thursday . The company traded as high as $1.21 and last traded at $1.21. 179,099 shares were traded during mid-day trading, a decline of 57% from the average session volume of 414,672 shares. The stock had previously closed at $1.10.
Dermata Therapeutics Stock Performance
The company has a market capitalization of $2.47 million, a PE ratio of -0.07 and a beta of 0.65. The company’s 50 day moving average price is $1.24 and its 200-day moving average price is $1.36.
About Dermata Therapeutics
Dermata Therapeutics, Inc, a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.
Recommended Stories
- Five stocks we like better than Dermata Therapeutics
- Health Care Stocks Explained: Why You Might Want to Invest
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
- Breakout Stocks: What They Are and How to Identify Them
- 3 Stocks to Buy While Others Stay on the Sidelines
- Comparing and Trading High PE Ratio Stocks
- MarketBeat Week in Review – 03/03 – 03/07
Receive News & Ratings for Dermata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
